课题基金 / 基金详情

Validation Of Novel Nutrient Formulation For Appetite Regulation

Validation Of Novel Nutrient Formulation For Appetite Regulation
用于食欲调节的新型营养配方的验证
批准号:
10028205
负责人:
金额:
$27.31万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2022
资助国家:
英国
项目状态:
已结题
起止时间:
2022 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Our scientific group has pioneered research on how our gut senses the contents of a meal since 1984\. This research has culminated in a major paper published this year showing our discovery of a novel and effective means to reduce appetite in obese people. Our company, Enterika, was set up to take this discovery to the market as a product that could then be made available for a very large unmet need -- appetite suppression and weight loss.For a while, it has been known that specialised cells in various parts of the intestine can sense different nutrients by specialised receptors (molecules) on the outsides of the cells lining the intestine wall. Our discovery was that targeting certain nutrients specifically to the lower gut (colon) gives rise to appetite suppression by activation of some of these specific sensor molecules. In turn, these cells then release hormones into the blood stream and activate sensory nerves leading to appetite suppression. A critical part of our discovery was that different nutrients act via different molecules, and only by combining the actions of more than one nutrient could we stimulate this process. Another critical finding was that naturally occurring dietary nutrients are effective in triggering this response in small quantities. This means our approach is drug-free, safe and could have broader health benefits.Our product currently consists of capsules filled with pure nutrient coated with a protective layer that only breaks down when it reaches the colon. However, many capsules are required before each meal. We aim to refine this formulation (based on recent advances in pharmacology) so it is smaller but still as effective. This will take more lab work to ensure the pathway of hormone release is adequately activated, and a clinical study in obese subjects to check that the capsules achieve their aim of inducing hormone changes and suppressing appetite. Further streamlining and optimisation will continue until we have the best product.To our knowledge, no other company or institution is pursuing the approach we have chosen. We are therefore in an ideal position to take these two clear steps towards occupying a substantial and successful part of the anti-obesity treatments market.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: